Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
MediWound Ltd. is a commercial-stage biopharmaceutical company focused on the development, manufacturing, and commercialization of enzymatic therapies for tissue repair, with a primary emphasis on severe burn care and chronic wound management. The company operates within the biotechnology and specialty pharmaceuticals industries, targeting hospital-based and specialty care settings. MediWound’s core revenue driver is its proprietary enzymatic debridement technology, which is designed to selectively remove non-viable tissue while preserving healthy tissue.
The company’s flagship product, NexoBrid®, is an FDA- and EMA-approved biologic for the removal of eschar in patients with deep partial- and full-thickness thermal burns. MediWound primarily serves burn centers, hospitals, and emergency preparedness agencies, including government stockpiling programs. Founded in 2000, the company is headquartered in Israel and has evolved from a development-stage biotechnology firm into a commercial organization following regulatory approvals in Europe and the United States.
Business Operations
MediWound operates largely as a single-segment biopharmaceutical company centered on enzymatic debridement therapies. Revenue generation is driven by sales of NexoBrid®, milestone payments, and procurement contracts, including government-sponsored emergency preparedness agreements. The company maintains in-house research and development, clinical operations, and biologics manufacturing capabilities, which are critical given the complex nature of its enzyme-based products.
Commercial operations span both domestic and international markets. MediWound conducts direct activities in Israel and the United States, while also relying on regional distributors and commercialization partners in parts of Europe and other international markets. The company has entered into strategic partnerships related to U.S. commercialization and government procurement, including long-term collaboration with U.S. government agencies for burn mass-casualty preparedness; specific commercial partner roles have been disclosed publicly but some operational details remain limited or vary across sources.
Strategic Position & Investments
MediWound’s strategic direction centers on expanding adoption of NexoBrid® in approved markets while advancing its clinical pipeline to address additional high-unmet-need indications. A key growth initiative is EscharEx®, an investigational enzymatic therapy being developed for chronic wounds such as venous leg ulcers. This program represents an effort to leverage the company’s enzymatic platform beyond burn care into broader wound management markets.
The company has benefited from significant non-dilutive funding and long-term procurement commitments from U.S. government agencies, including the Biomedical Advanced Research and Development Authority (BARDA), supporting both development and stockpiling of NexoBrid®. MediWound has not disclosed a diversified portfolio of subsidiaries; instead, it maintains a focused operating structure built around its core technology platform. No major acquisitions have been publicly confirmed beyond licensing and collaboration agreements.
Geographic Footprint
MediWound is headquartered in Israel, where it maintains executive leadership, research and development, and manufacturing operations. The company has a significant operational presence in the United States, reflecting the importance of the U.S. burn care market and government preparedness programs. Regulatory approvals and commercial activity extend across Europe, where NexoBrid® has been approved and used for more than a decade.
Beyond these core regions, MediWound has an international footprint supported by distributors and strategic partners, allowing access to additional markets in Latin America, Asia-Pacific, and other regions. Its global reach is shaped primarily by regulatory approvals, hospital infrastructure, and government-level engagement in burn and trauma preparedness.
Leadership & Governance
MediWound was founded by a group of scientists and entrepreneurs focused on enzyme-based therapeutics; individual founder attribution varies across public disclosures, and some early leadership details are inconclusive based on available public sources. The company is led by an executive team with experience in global pharmaceuticals, biologics development, and regulated healthcare markets. Management emphasizes disciplined clinical development, regulatory compliance, and long-term value creation through focused innovation.
Key executives include:
- Sharon Malka – President and Chief Executive Officer
- Ido Hadari – Chief Financial Officer
- Dr. Ram Selvaraju – Chief Medical Officer
- Michael H. Friedman – Chairman of the Board
The leadership team’s strategic vision centers on expanding the clinical and commercial impact of MediWound’s enzymatic platform while maintaining a lean organizational structure aligned with specialty biologics markets.